Scientists in Amsterdam Just Destroyed Breast Cancer in 11 Days Without Chemo

European scientists have finally discovered a real breakthrough for the most common cancer type in women- breast cancer!

One of the most common type of cancer for women is breast cancer. It is estimated that one in 8 women at some point of her life will develop breast cancer. But now, there is new hope. Group of scientists from Amsterdam may have discovered a cure that can save millions of life.

At the European Breast Cancer Conference in Amsterdam, professor Nigel Bundred presented the findings of a recent research which served to evaluate the effects of a couple of drugs, Herceptin (a.k.a trastuzumab) and Lapatinib.

These medicaments have been used in the treatment of cancer already, but this was the first time they were used together in combination, before any other conventional treatments, like surgery or chemo.

Scientists have found that this combination effectively destroys breast cancer in only 11 days!

Cancer Research Uk funded this research. The main goal was to determine the influence of the combination of these two drugs on human epidermal growth factor receptor 2 or HER2. This protein influence the growth and development of cancer cells.

The best thing about this method is that leaves out surgery and chemotherapy and all of their side effects.

We are becoming aware that chemo is far from a beneficial treatment, so it is more than welcome to avoid this treatment and try some other alternatives.

This research involved 257 women with HER2 positive breast cancer. The first group, half of the women, were controlled group receiving only Herceptin. The rest of the women received the combination of the two drugs mentioned above.

The results were as follows: 11% of those women who took the drug combo had no cancer cells remaining within two weeks and 17% of cases featured dramatically shrunken tumors.

In comparison to the control group, they had 0% with no trace of cancer cells and only 3% showed a drop in tumor size.

Therefore, the combination of the drugs has extremely beneficial effects in the case of breast cancer, as opposed to their results if used on their own. Yet, the issue is that licensing allows its use only alongside chemo, and not alone. Yet, these findings may contribute for a change.

This study is a big step forward in the fight against the breast cancer. And it is a soil for examining further on and improving the initial findings.

Yet, it provides hope that scientists are working hard to find the cure, so we are eagerly waiting for new improvements on the field!